Clinical trial registry record

18F-MFBG PET Imaging of the Norepinephrine Transporter in Neural Crest and Neuroendocrine Tumors

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Terminated.
Evidence
Registered phase 1 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated August 12, 2022.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT04258592
Last registry update
August 12, 2022
Status
Terminated
Phase
Phase 1
Sponsor
Universitaire Ziekenhuizen KU Leuven
Enrollment
6
Countries
Belgium
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1
Study design
NA · SINGLE GROUP · DIAGNOSTIC · NONE
Evidence population
Human clinical study registration
Participants
6
Population
ALL · 1 Year
Duration
2020-02-07 to 2022-07-07
Intervention
(18F)MFBG; PET/CT; Venous blood samples
Comparator
Not reported
Outcomes measured
Confirmation of 18F-MFBG as a hNET imaging agent in patients with neural crest and neuroendocrine tumors. — 20 months; Normal-organ and tumor uptake of 18F-MFBG as a function of time — 20 months; Identify the ideal time point for imaging after 18F-MFBG injection. — 20 months; Safety analysis of 18F-MFBG administration: Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 — 20 mo…; Assessment of lesion targeting by 18F-MFBG as compared to 123I-MIBG — 20 months
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Cancer and ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

cancer and aging
Read the original source →Export JSON